Category and country
Therapeutics companies in Poland
8 therapeutics profiles in Poland. Every profile is hand-reviewed with leadership, certifications, and public sources.
Where does therapeutics cluster in Poland?
Gdansk (2), Wroclaw (2), Krakow (1), and Łomianki (1) Most visible profiles: BioResearch Pharma S.A., Biotts S.A., Human Biome Institute S.A., and Pikralida Sp. z o.o..
Which standards are already visible?
GMP (2) and GLP (1) Latest review: 24 April 2026. Review cycle: April 2026.
Full list
Therapeutics profiles in Poland
8 profiles match the active filter.
Current review cycle
BioResearch Pharma S.A.
WarsawPolandTherapeutics
Warsaw pharmaceutical R&D company focused on drug repositioning for dermatology, with programs in androgenetic alopecia and psoriasis and active BioInMed cluster membership.
- Lead
- Lukasz ZybaczynskiChief Executive Officer and Co-Founder
- Scale
- Drug-repositioning R&D
Current review cycle
Biotts S.A.
WroclawPolandTherapeutics
Wroclaw drug-delivery biotech with the MTC-Y Multifunctional Transdermal Carrier platform for transdermal insulin, oncology, and diabetes formulations, partnered with BIOTON.
- Lead
- Jan Henk HendriksChief Executive Officer
- Scale
- Transdermal drug-delivery R&D
Current review cycle
Human Biome Institute S.A.
GdanskPolandTherapeutics
Gdansk microbiome biotherapeutics company operating a Microbiota Center for GMP fecal microbiota transplantation production, with Polish Medical Research Agency-funded clinical trials and biosynthetic donor-independent microbiome programs.
- Lead
- Jaroslaw BilinskiChief Executive Officer
- Scale
- GMP FMT production and clinical development
Current review cycle
Pikralida Sp. z o.o.
PoznanPolandTherapeutics
Poznan drug-discovery biotech (Adam Mickiewicz University spin-out) focused on neurological disorders and age-related civilizational diseases, with medicinal-chemistry and R&D collaborations.
- Lead
- Stanislaw PikulPresident and Co-Founder
- Scale
- Preclinical small-molecule development
Current review cycle
PolTREG S.A.
GdanskPolandTherapeutics
Gdansk clinical-stage cell therapy biotech developing T-regulatory cell therapies for autoimmune diseases (Type 1 diabetes, multiple sclerosis), with GMP Treg manufacturing and a Warsaw Stock Exchange listing (PTG).
- Lead
- Piotr TrzonkowskiChief Executive Officer and Co-Founder
- Scale
- GMP cell-therapy manufacturing
Current review cycle
Bioceltix
WroclawPolandTherapeutics
Wroclaw veterinary biologics company developing allogeneic cell therapies and regulated animal-health products.
- Lead
- Łukasz BzdzionPresident of the Management Board
- Scale
- Veterinary biologics platform
Current review cycle
Ryvu Therapeutics
KrakowPolandTherapeutics
Clinical-stage oncology drug discovery and development platform in Krakow focused on small-molecule therapies against emerging cancer targets.
- Lead
- Pawel PrzewiezlikowskiChief Executive Officer and President of the Management Board
- Scale
- Clinical-stage drug discovery
Current review cycle
Celon Pharma S.A.
ŁomiankiPolandTherapeutics
Integrated oncology and neurology R&D platform with in-house development, manufacturing, and commercial drug operations in Poland. The verified March 2026 record positions Celon as a high-conviction therapeutic innovation anchor in the cluster.
- Lead
- Dr. Maciej WieczorekCEO and President of the Management Board
- Scale
- Integrated therapeutic R&D and manufacturing
Related brief
Read deeper on this category
EU Biotech Regulation 2026: What Changed and Who It Affects
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefFAQ
Frequently asked questions on this category
- What does "therapeutics company" mean?
- A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.
- Which European countries lead in therapeutics?
- Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.
- How are therapeutics companies verified in this directory?
- Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.
- Can I compare two therapeutic developers side by side?
- Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.
Next step
Compare companies or open the wider market.
Use the compare tool to view two or three companies side by side, or open the country hub for the full market view.